Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)" aimed at supporting research projects focused on the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer's Disease-Related Dementias (ADRD). The initiative seeks to address challenges in the delivery, safety, manufacturability, and clinical testing of these therapies, with an emphasis on projects that can advance through the translational pipeline, including IND development and early clinical evaluation. With an estimated total program funding of $6 million and an expected three awards, this opportunity is open to a diverse range of applicants, including Indian/Native American Tribal Governments, eligible federal agencies, and foreign institutions. Interested parties can reach out to the NINDS ADRD Program via email at nindsdonadrd@mail.nih.gov, with key deadlines including an estimated synopsis post date of July 1, 2026, and a close date of November 10, 2026.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).